NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its fourth quarter and full year 2022 financial results before the market opens on Tuesday, March 21, 2023. Members of the MiNK leadership team will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update.
Conference Call
Dial in numbers: 646-307-1963 (USA-NY), 800-715-9871 (USA & Canada)
Conference ID: 6075772
Webcast
A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/ctv5wn5g.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.
Contact
Alexa Buffa
781-674-4428
communications@minktherapeutics.com
Investor relations:
Zack Armen
917-362-1370
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…
This strategic partnership is a bold move that brings peak performance to the pickleball court,…
GRAND RAPIDS, Mich., June 4, 2025 /PRNewswire/ -- Cirius Therapeutics, Inc., developing innovative therapies for patients…
SAVANNAH, Ga., June 3, 2025 /PRNewswire/ -- Catalis Dental Lab Partners ("Catalis") announced two significant…
BANNING, Calif., June 4, 2025 /PRNewswire/ -- Blue Zones Project invites the community to their…
ISS National Lab-sponsored research on Axiom Mission 4 tests wearable tech to collect, analyze sleep…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
